0001209191-17-014829.txt : 20170227 0001209191-17-014829.hdr.sgml : 20170227 20170227165447 ACCESSION NUMBER: 0001209191-17-014829 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170223 FILED AS OF DATE: 20170227 DATE AS OF CHANGE: 20170227 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRIEDMAN PAUL A CENTRAL INDEX KEY: 0001236927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 17642641 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-23 0 0000879169 INCYTE CORP INCY 0001236927 FRIEDMAN PAUL A 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 1 0 0 0 Common Stock 2017-02-23 4 M 0 50000 18.32 A 347518 D Common Stock 2017-02-23 4 S 0 50000 120.32 D 297518 D Non-Qualified Stock Option (right to buy) 18.32 2017-02-23 4 M 0 50000 0.00 D 2020-02-08 Common Stock 50000 144542 D Represents weighted average sale price. Actual sale prices ranged from $120.00 - $120.64. Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. /s/ Paul A. Friedman 2017-02-27